There is a serious lack of testing of medicinal products in the paediatric population. The European Commission has attempted to provide a structural solution by drafting a regulation. This report describes the economic, social, sustainable, and environmental impacts of the regulation. The assessment indicates that the proposed regulation will achieve its objectives, although the effects will vary.
The research described in this report was conducted by RAND Europe for the European Commission.
This report is part of the RAND Corporation Monograph series. RAND monographs present major research findings that address the challenges facing the public and private sectors. All RAND monographs undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.